阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

盘前交易 03-30 04:01:13 EDT

188.42

+5.02

+2.74%

盘前191.37

+2.95+1.57%

04:01 EDT

最高192.97	最低187.95	成交量276.30万
今开190.88	昨收183.40	日振幅2.74%
总市值2,922亿	流通市值2,909亿	总股本15.51亿
成交额5.26亿	换手率0.18%	流通股本15.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":188.42,"timestamp":1774641600000,"preClose":183.4,"halted":0,"volume":2762995,"hourTrading":{"tag":"盘前","latestPrice":191.3727,"preClose":188.42,"latestTime":"04:01 EDT","volume":204,"amount":38980.41384,"timestamp":1774857662835,"change":2.9527,"changeRate":0.015671,"amplitude":0.00121},"delay":0,"changeRate":0.027371864776444828,"floatShares":1544000000,"shares":1551000000,"eps":6.54,"marketStatus":"盘前交易","change":5.02,"latestTime":"03-30 04:01:13 EDT","open":190.88,"high":192.97,"low":187.95,"amount":525692429.72095,"amplitude":0.027372,"askPrice":191.33,"askSize":420,"bidPrice":190.97,"bidSize":100,"shortable":3,"etf":0,"ttmEps":6.54,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774877400000},"marketStatusCode":1,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":188.42,"dividendRate":0.0166,"preHourTrading":{"tag":"盘前","latestPrice":191.3727,"preClose":188.42,"latestTime":"04:01 EDT","volume":204,"amount":38980.41384,"timestamp":1774857662835,"change":2.9527,"changeRate":0.015671,"amplitude":0.00121},"postHourTrading":{"tag":"盘后","latestPrice":189.05,"preClose":188.42,"latestTime":"19:40 EDT","volume":1841,"amount":347281.3295,"timestamp":1774654816580,"change":0.63,"changeRate":0.003344,"amplitude":0.003344},"volumeRatio":1.5340077247969124,"impliedVol":0.3214,"impliedVolPercentile":0.888},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2623369335","title":"加科思-B(01167)收到阿斯利康就泛KRAS抑制剂JAB-23E73订立的许可及合作协议项下的1亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2623369335","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623369335?lang=zh_cn&edition=full","pubTime":"2026-03-30 08:02","pubTimestamp":1774828968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，加科思-B(01167)发布公告，内容有关北京加科思新药研发有限公司(北京加科思，本集团的非全资附属公司)与AstraZeneca AB(阿斯利康)订立了许可与合作协议。本公司的附属公司北京加科思就其订立的许可及合作协议，已收到阿斯利康支付的1亿美元的首付款。该首付款的到账，进一步充盈了本集团的现金储备，也将为本集团后续创新肿瘤疗法管线研发的推进提供助力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421428.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2417539215.USD","BK4568","BK1161","01167","LU0109394709.USD","LU0889565916.HKD","LU1829250122.USD","LU0289739699.SGD","LU2236285917.USD","LU0320765992.SGD","LU2456880835.USD","AZN","BK4585","BK4588","BK4007","IE00B3T34201.USD","LU2462157665.USD","LU0058720904.USD","BK1574"],"gpt_icon":0},{"id":"1197644035","title":"阿斯利康COPD试验取得积极成果，股价应声大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1197644035","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197644035?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:38","pubTimestamp":1774625932,"startTime":"0","endTime":"0","summary":"阿斯利康股价周五上涨约3.5%，此前该公司宣布其用于治疗慢性阻塞性肺病（COPD）的药物在两项大型试验中成功延缓了患者的症状恶化。COPD是一种致命的肺部疾病，通常由吸烟引起。\n该药物名为torzorakimab，其作用机制是通过减轻炎症和改善黏液功能失调来发挥作用——这两者正是COPD病情发展的关键驱动因素。慢性阻塞性肺病常被认为是全球第三大死亡原因。\n在这两项试验中，无论是当前吸烟者还是既往吸烟者，接受该药物治疗的患者发生中度至重度COPD急性加重的比率，均低于未使用该药物的对照组。\n尽管周五股价有所上涨，但阿斯利康的股价在整个三月份仍累计下跌约8%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","BK4585","LU2456880835.USD","LU0058720904.USD","AZN","LU2417539215.USD","LU2462157665.USD","BK4007","IE00B3T34201.USD","LU0289739699.SGD","LU0109394709.USD","LU1829250122.USD","LU2236285917.USD","BK4568","BK4588","LU0320765992.SGD"],"gpt_icon":0},{"id":"2622878036","title":"阿斯利康涨3.5%，其肺病药物临床试验意外取得成功（竞品均已失败）","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878036","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622878036?lang=zh_cn&edition=full","pubTime":"2026-03-27 22:47","pubTimestamp":1774622820,"startTime":"0","endTime":"0","summary":"阿斯利康称，呼吸类药物 托佐利单抗 与安慰剂相比，在既往吸烟人群及总体患者中均减少了慢性阻塞性肺疾病的急性加重发作。　　阿斯利康表示，完整试验数据将在即将召开的医学会议上公布。　　阿斯利康在纽约上市的股票早盘逆势上涨3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-27/doc-inhsmxrn5148304.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","BK4588","LU0289739699.SGD","LU0320765992.SGD","BK4007","LU2417539215.USD","LU2456880835.USD","BK4568","LU2462157665.USD","LU0109394709.USD","AZN","LU0058720904.USD"],"gpt_icon":0},{"id":"1181163440","title":"开盘 | 美股三大指数集体低开，Unity逆势飙升逾17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181163440","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1181163440?lang=zh_cn&edition=full","pubTime":"2026-03-27 21:30","pubTimestamp":1774618230,"startTime":"0","endTime":"0","summary":"3月27日，美股三大指数集体低开，道指跌0.21%，标普500指数跌0.36%，纳指跌0.55%。Unity涨超17%，该公司公布的初步第一季度业绩超出指引，并宣布计划退出非战略性广告业务；Argan涨超24%，第四季度营收同比增长12.7%，盈利远超市场预期；阿斯利康涨近4%，该公司表示潜在的肺部疾病药物在3期研究中达到主要终点。","market":"us","thumbnail":"https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/ff6e3231d788a5a6d28cf7965385cc7f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ef1441e3251e3e6a7de1cfe4fd8eaf07","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2462157665.USD","LU0289739699.SGD","SPY","LU0058720904.USD",".IXIC","LU2417539215.USD",".SPX","BK4007","IE00B3T34201.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","AZN","LU2456880835.USD",".DJI","BK4588","BK4568","YMmain","NQmain","LU1829250122.USD","BK4585","LU2236285917.USD"],"gpt_icon":0},{"id":"2622884228","title":"阿斯利康ADC药物新适应证在中国实现“全球首发”","url":"https://stock-news.laohu8.com/highlight/detail?id=2622884228","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622884228?lang=zh_cn&edition=full","pubTime":"2026-03-27 17:20","pubTimestamp":1774603200,"startTime":"0","endTime":"0","summary":"南方财经3月27日电，据第一财经，阿斯利康宣布，公司与第一三共联合开发的德曲妥珠单抗（优赫得）正式获得中国药监局批准，用于高危HER2阳性II期或III期乳腺癌成人患者的新辅助治疗，这是该适应证的全球首次获批，中国获批早于美国、欧洲等全球其他市场。新辅助治疗是手术前进行的抗肿瘤治疗。这款药物也成为全球首个且唯一获批用于HER2阳性乳腺癌新辅助治疗的ADC药物。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273687120276.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0889565916.HKD","LU2462157665.USD","LU1829250122.USD","LU2417539215.USD","BK4007","BK4585","LU0289739699.SGD","LU2236285917.USD","LU0058720904.USD","BK4568","BK4588","LU0320765992.SGD","LU2456880835.USD","AZN","BK4231","BK4080","IE00B3T34201.USD","LU0109394709.USD","ADC"],"gpt_icon":0},{"id":"2622857839","title":"阿斯利康溥思同：亚太不仅是增长引擎，也是技术创新的中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2622857839","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622857839?lang=zh_cn&edition=full","pubTime":"2026-03-26 20:05","pubTimestamp":1774526700,"startTime":"0","endTime":"0","summary":"　　3月26日，博鳌亚洲论坛2026年年会于3月24日至27日在海南博鳌举行。在《重新理解ESG：企业的责任与机遇》论坛上，阿斯利康全球高级副总裁、亚太和日本地区供应链负责人溥思同表示，“在阿斯利康我们每天的工作中都要践行ESG，而且它是我们的可持续增长和价值观所在。”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-03-26/doc-inhsiqkn0080193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B3T34201.USD","LU0109394709.USD","LU2236285917.USD","BK4568","LU2462157665.USD","LU2417539215.USD","LU1829250122.USD","LU2456880835.USD","BK4585","BK4588","LU0058720904.USD","LU0320765992.SGD","AZN","LU0889565916.HKD","LU0289739699.SGD","BK4007"],"gpt_icon":0},{"id":"2620639226","title":"外资再加码！医药巨头阿斯利康核药生产供应基地落子黄埔","url":"https://stock-news.laohu8.com/highlight/detail?id=2620639226","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620639226?lang=zh_cn&edition=full","pubTime":"2026-03-19 21:36","pubTimestamp":1773927412,"startTime":"0","endTime":"0","summary":"3月19日，阿斯利康与广州经济技术开发区管理委员会正式签署战略合作框架协议，宣布将在广州开发区、黄埔区建设放射性偶联药物（RDC）生产供应基地。这是阿斯利康今年1月宣布系列投资中的重要一环，标志着这家全球生物医药巨头在核药这一前沿赛道完成战略布局的关键落子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603193677730187.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677730187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","LU0289739699.SGD","LU0320765992.SGD","BK1515","159938","LU0109394709.USD","IE00B3T34201.USD","LU0058720904.USD","BK1574","BK1161","LU2462157665.USD","LU0889565916.HKD","LU2417539215.USD","BK4568","BK4588","LU2456880835.USD","LU1829250122.USD","AZN","BK4007","LU2236285917.USD","BK4585"],"gpt_icon":0},{"id":"2620003241","title":"阿斯利康将于广州建设放射性偶联药物生产供应基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2620003241","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620003241?lang=zh_cn&edition=full","pubTime":"2026-03-19 19:01","pubTimestamp":1773918091,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0058720904.USD","IE00B3T34201.USD","LU2456880835.USD","LU1829250122.USD","LU0109394709.USD","LU0320765992.SGD","LU2417539215.USD","BK4585","LU0289739699.SGD","AZN","BK4568","LU0889565916.HKD","BK4007","BK4588","LU2236285917.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"1111610205","title":"Talzenna联合Xtandi显著改善转移性前列腺癌患者的影像学无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1111610205","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111610205?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:46","pubTimestamp":1773917215,"startTime":"0","endTime":"0","summary":"一项最新研究显示，将Talzenna与Xtandi联合使用，可显著提升转移性前列腺癌患者的影像学无进展生存期。这一积极结果有望为晚期前列腺癌的治疗提供新的有效方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","LU0306807586.USD","LU0868494617.USD","LU1066053197.SGD","LU1023059063.AUD","BK4585","LU0306806265.USD","IE00BLSP4452.SGD","BK4534","LU1894683348.USD","SG9999001176.USD","SG9999002232.USD","BK4581","LU0289739699.SGD","LU0058720904.USD","BK4588","BK4550","IE0002270589.USD","LU0225284248.USD","IE00B19Z3581.USD","LU1057294990.SGD","BK4568","LU1066051498.USD","LU0985481810.HKD","SGXZ57979304.SGD","IE00BLSP4239.USD","AZN","BK4007","PFE","BK4599","SG9999002224.SGD","BK4533","LU0321505868.SGD","LU1883839398.USD","LU0321505439.SGD","SG9999003800.SGD","LU0122379950.USD","IE00BBT3K403.USD","IE000M9KFDE8.USD","LU0170899867.USD","SG9999001176.SGD","SG9999013999.USD","BK4592","LU0225771236.USD","LU0456855351.SGD","LU0234572021.USD","SG9999011175.SGD","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2620021540","title":"落子上海细胞治疗全链条，阿斯利康“深耕中国”迈入新阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2620021540","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620021540?lang=zh_cn&edition=full","pubTime":"2026-03-19 12:52","pubTimestamp":1773895925,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛上海报道在英国首相斯塔默访华带来中英经贸暖风的两个月后，英国制药巨头阿斯利康用实际行动为这一轮双边合作添上了浓墨重彩的一笔。3月19日，阿斯利康正式宣布了一项具有里程碑意义的布局：计划在上海建立细胞疗法商业化生产供应基地与创新中心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603193677171431.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677171431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0320765992.SGD","LU2236285917.USD","LU0058720904.USD","LU1829250122.USD","LU0289739699.SGD","LU0889565916.HKD","LU2462157665.USD","LU2417539215.USD","IE00B3T34201.USD","BK4588","BK4007","BK4585","BK4568","LU0109394709.USD","LU2456880835.USD","AZN"],"gpt_icon":0},{"id":"2620290003","title":"阿斯利康宣布在上海建立细胞疗法商业化生产供应基地与创新中心","url":"https://stock-news.laohu8.com/highlight/detail?id=2620290003","media":"南方财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620290003?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:54","pubTimestamp":1773888854,"startTime":"0","endTime":"0","summary":"南方财经3月19日电，阿斯利康今日宣布，计划在上海建立细胞疗法商业化生产供应基地与创新中心，将成为首家在中国拥有端到端细胞治疗能力的全球领先生物制药企业。同日，公司与上海市科学技术委员会及英国领先科研与金融机构签署多方合作谅解备忘录。据悉，阿斯利康将在上海自贸区临港新片区建设专门的细胞疗法商业化生产供应基地，用于在中国及其他亚洲市场商业化生产及供应自体CAR-T细胞疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677128937.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0058720904.USD","IE00B3T34201.USD","LU2456880835.USD","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD","LU1829250122.USD","BK4588","LU0889565916.HKD","LU0320765992.SGD","BK4007","LU2462157665.USD","BK4585","BK4568","AZN","LU0289739699.SGD"],"gpt_icon":0},{"id":"2620297573","title":"阿斯利康中国区副总裁黄彬突然离职","url":"https://stock-news.laohu8.com/highlight/detail?id=2620297573","media":"消费日报财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620297573?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:59","pubTimestamp":1773885577,"startTime":"0","endTime":"0","summary":"3月18日，阿斯利康中国方面向记者确认，公司资深高管、阿斯利康中国副总裁、市场准入部门负责人黄彬正式离任。该人士为阿斯利康任职超20年的元老级高管，主导中国市场准入核心业务。截至记者发稿，黄彬本人暂未对外披露后续职业安排。公开资料显示，黄彬，1967年生，中国国籍，无境外永久居留权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193677031788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2462157665.USD","BK4007","LU0289739699.SGD","AZN","IE00B3T34201.USD","LU2456880835.USD","LU1829250122.USD","LU0109394709.USD","BK4585","LU0058720904.USD","LU0320765992.SGD","BK4588","BK4568","LU0889565916.HKD","LU2417539215.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2619049151","title":"阿斯利康(AZN.US)两款肿瘤药将接受FDA专家小组审判","url":"https://stock-news.laohu8.com/highlight/detail?id=2619049151","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619049151?lang=zh_cn&edition=full","pubTime":"2026-03-13 07:00","pubTimestamp":1773356416,"startTime":"0","endTime":"0","summary":"近日，FDA官网宣布将在2026年4月30日召开肿瘤药物咨询委员会(ODAC)会议。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313070054_25816.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0058720904.USD","IE00B3T34201.USD","LU2456880835.USD","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD","LU1829250122.USD","BK4588","LU0889565916.HKD","LU0320765992.SGD","BK4007","LABU","LU2462157665.USD","BK4585","BK4568","AZN","LU0289739699.SGD"],"gpt_icon":0},{"id":"2618130770","title":"Abivax否认法国媒体报道的阿斯利康收购传闻","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130770","media":"环球市场播报","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618130770?lang=zh_cn&edition=full","pubTime":"2026-03-12 23:07","pubTimestamp":1773328020,"startTime":"0","endTime":"0","summary":"法国生物技术公司Abivax周四否认法国媒体关于阿斯利康正在谈判收购该公司的报道。\n　　此前La Lettre的报道称，阿斯利康自2月初以来一直拥有接触Abivax数据的独家权限，并有直到3月23日的时间来正式提出收购要约。\n　　Abivax发言人表示，他们完全否认这一报道，但没有进一步评论文章中的具体内容。阿斯利康早些时候拒绝置评。\n　　数月来，Abivax多次被传为是收购对象，其股价也因此飙升。\n　　在La Lettre的报道发布后，该公司股价周四一度上涨15%，但在午盘交易中涨幅约为4%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-12/doc-inhqtyyi4639257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU1829250122.USD","LU2236285917.USD","BK4588","LU0289739699.SGD","LU0320765992.SGD","BK4007","LU2417539215.USD","LU2456880835.USD","BK4568","LU2462157665.USD","LU0109394709.USD","AZN","LU0058720904.USD"],"gpt_icon":0},{"id":"2618791903","title":"港股异动 | 康诺亚-B(02162)再涨超3% CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618791903","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618791903?lang=zh_cn&edition=full","pubTime":"2026-03-12 09:51","pubTimestamp":1773280266,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B再涨超3%，截至发稿，涨2.21%，报55.5港元，成交额750.96万港元。根据许可协议条款及条件的规限下，上述临床试验完成首例受试者给药已触发相关里程碑付款，总金额为4500万美元。阿斯利康已支付该里程碑款项。公开资料显示，康诺亚和乐普生物合资设立的KYM Biosciences Inc.于2023年2年与阿斯利康订立全球独家许可协议，授权阿斯利康在全球范围开发及商业化CMG901。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412917.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","AZN","LU1829250122.USD","LU0058720904.USD","BK4588","LU2462157665.USD","IE00B3T34201.USD","BK1587","BK1583","LU2236285917.USD","02162","LU0289739699.SGD","VXUS","LU2417539215.USD","LU0889565916.HKD","BK4568","LU2456880835.USD","LU0109394709.USD","BK4007","BK1574","LU0320765992.SGD"],"gpt_icon":0},{"id":"2618924896","title":"英国央行降息预期减弱拖累富时100指数跌0.8% 阿斯利康与汇丰领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2618924896","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618924896?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:55","pubTimestamp":1773219310,"startTime":"0","endTime":"0","summary":"（原标题：英国央行降息预期减弱拖累富时100指数跌0.8% 阿斯利康与汇丰领跌）金吾财讯|伦敦富时100指数周三延续跌势，下挫0.8%至10320点，因投资者调降对英国央行年内进一步降息的预期。权重股阿斯利康、汇丰控股与罗尔斯·罗伊斯引领大盘普跌，仅零售板块因Inditex亮眼财报获得支撑。尽管原油价格已从每桶100美元上方高位回落，但早前涨势已重塑市场预期——货币市场现预计2026年前降息概率微乎其微。企业财报方面，保险及投资管理集团Legal & General年度盈利虽增并宣布12亿英镑股票回购计划，但因偿付能力比率未达预期，股价重挫近6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117061397ad6c1c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117061397ad6c1c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU1267930227.SGD","HSBH","BK4521","AZN","IE00B3T34201.USD","LU2456880835.USD","HSBC","BK4207","BK4588","BK4568","BK4585","LU0058720904.USD","LU2462157665.USD","LU0109394709.USD","LU2236285917.USD","BK4007","LU0128525689.USD","LU2417539215.USD","LU1829250122.USD","LU0310800965.SGD","LU0052756011.USD","LU0289739699.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","NVOX","INCY","LU0757428866.USD","BK4532","NVOH","BK4599","REGN","BK4530","BK4007","BK4588","IE00BKVL7J92.USD","LU0029874061.USD","AZN","IE00BZ1G4Q59.USD","IE00BFMHRM44.USD","BK4121","LU0390134368.USD","LU0128526141.USD","LU1815336091.USD","BK4585","LU0154236417.USD","LU1093756168.USD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2618996353","title":"港股异动 | 加科思-B(01167)绩后涨超6% 2025年研发管线多点突破 与阿斯利康共同开发JAB-23E73","url":"https://stock-news.laohu8.com/highlight/detail?id=2618996353","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618996353?lang=zh_cn&edition=full","pubTime":"2026-03-11 09:35","pubTimestamp":1773192931,"startTime":"0","endTime":"0","summary":"截至2025年12月31日，公司拥有380项在全球提交的有效专利或专利申请，其中146项专利已在全球主要市场获颁发或允许。年内，公司与AstraZeneca AB已订立许可与合作协议，共同开发及商业化泛KRAS抑制剂JAB-23E73。根据该许可及合作协议并受其条款及条件所限，北京加科思有权向阿斯利康收取1亿美元的预付款项，并有资格在达成特定开发、监管及商业里程碑时收取额外里程碑付款，总潜在代价最高可达19.15亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1412445.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4568","IE00B3T34201.USD","VXUS","LU2236285917.USD","LU2456880835.USD","LU2462157665.USD","BK1161","LU2417539215.USD","BK4585","LU0109394709.USD","LU0289739699.SGD","LU0320765992.SGD","LU0058720904.USD","LU1829250122.USD","BK4007","BK1574","BK4588","AZN","01167","LU0889565916.HKD"],"gpt_icon":0},{"id":"2618939295","title":"康诺亚CMG901获阿斯利康4500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939295","media":"北京商报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939295?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:18","pubTimestamp":1773137907,"startTime":"0","endTime":"0","summary":"北京商报讯3月10日，康诺亚发布公告，更新了与AstraZeneca（阿斯利康）就核心产品CMG901（AZD0901）合作的最新情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603103667582417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603103667582417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2462157665.USD","BK1587","LU0289739699.SGD","LU0058720904.USD","LU2417539215.USD","BK4007","BK1574","IE00B3T34201.USD","LU0109394709.USD","LU0320765992.SGD","LU0889565916.HKD","AZN","LU2456880835.USD","BK4588","BK4568","BK1161","LU1829250122.USD","02162","BK1583","BK4585","LU2236285917.USD"],"gpt_icon":0},{"id":"2617635561","title":"顶尖药企竞相推出减重口服药","url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:16","pubTimestamp":1772806560,"startTime":"0","endTime":"0","summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BLSP4452.SGD","LU2328871848.SGD","LU1894683348.USD","SGXZ57979304.SGD","BK4585","SG9999011175.SGD","LU0868494617.USD","LU2242644610.SGD","LU2097828631.EUR","BK4581","LU2097828474.EUR","AZN","LU0225771236.USD","BK4568","LU1066051498.USD","LU0289739699.SGD","LU1894683264.USD","BK1161","BK4007","MRK","SG9999001176.SGD","PFE","BK4550","SG9999013999.USD","VKTX","LU0321505868.SGD","LU1969619763.USD","LU2097828805.USD","LU0456855351.SGD","HK0000165453.HKD","BK1589","IE00B19Z3B42.SGD","LU0122379950.USD","LU1883839398.USD","LU2097828714.EUR","LU0306806265.USD","BK4534","BK4588","LU0455707207.USD","LU0170899867.USD","RHHBY","000963","01801","BK4599","IE00BLSP4239.USD","LU0058720904.USD","LU0234572021.USD","LU0306807586.USD","LU1066053197.SGD","IE0002270589.USD","IE00BBT3K403.USD","LU0502904849.HKD","LU0985481810.HKD","IE00B19Z3581.USD","LU1057294990.SGD","IE000M9KFDE8.USD","SG9999002224.SGD","SG9999001176.USD","LU0321505439.SGD","NVO","SG9999002232.USD","SG9999003800.SGD","BK1583","BK4533","LU0225284248.USD","LU2488822045.USD","BK4592","LLY","LU1023059063.AUD","LU2097828557.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":0.0263},{"period":"1month","weight":-0.0844},{"period":"3month","weight":0.0141},{"period":"6month","weight":0.2773},{"period":"1year","weight":0.2934},{"period":"ytd","weight":0.0248}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.024232},{"month":4,"riseRate":0.65625,"avgChangeRate":0.031251},{"month":5,"riseRate":0.53125,"avgChangeRate":0.008752},{"month":6,"riseRate":0.454545,"avgChangeRate":0.018334},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}